XENOGENEIC NATURAL ANTIBODY TARGETS--STRUCTURE/FUNCTION

异种天然抗体靶标——结构/功能

基本信息

  • 批准号:
    2519425
  • 负责人:
  • 金额:
    $ 30.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1993
  • 资助国家:
    美国
  • 起止时间:
    1993-09-01 至 1998-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Adapted from the applicant's abstract) Transplantation is the preferred therapy for chronic and sometimes for acute failure of the kidney, heart, liver and lungs. The clinical application of transplantation is limited not so much by immune mediated rejection as it is by the number of donors. Thus, fewer than half of those who need organ transplants actually received them and those who do receive transplants must wait for months and sometimes years to receive an organ. This problem could be overcome if animal organs, the pig being generally preferred, were used in lieu of human organs for transplantation. However, clinical xenotransplantation, as such, is prevented by very rapid and severe rejection reactions that destroy the graft over a period of hours to days. Recent studies have revealed that the most severe types of xenografts rejection are initiated by two factors. One is the reaction of natural antibodies of the recipient with antigens in the donor organ, activating the complement system. The other factor is the incompatibility of complement regulatory proteins of the donor organ with the complement system of the recipient, rendering the xenogeneic organ highly susceptible in inadvertent injury by complement. The second problem has been overcome by the development of transgenic pigs, expressing human complement regulatory proteins. The problem posed by xenoreactive antibodies and the antigens they recognize is the subject of this application. The overall objectives of the proposed research are first to identify the actual porcine endothelial cell antigens recognized by human xenoreactive natural antibodies and the antibodies elicited by exposure to a xenogeneic organ and determine the rules governing antibody-antigen interaction. Based on strong evidence that the major epitope recognized by natural antibodies is a carbohydrate, Gala1-3Gal, several strategies are proposed which would eliminate the expression of that carbohydrate from a donor organ. Second, the physiologic consequences of the interaction between xenoreactive antibodies and their corresponding targets on endothelial cells will be elucidated. These studies will focus on the coagulant properties of endothelium and the changes in structure and function induced by complement. Therapeutic approaches to dealing with aberrant physiology will be investigated.
描述:(改编自申请人摘要)移植是

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeffrey L Platt其他文献

THE NATURE OF THE SURFACE CARBOHYDRATES ON PORCINE CELLS WHICH ARE NOT RECOGNIZED BY HUMAN NATURAL ANTIBODIES. • 125
  • DOI:
    10.1203/00006450-199604001-00144
  • 发表时间:
    1996-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Beatrice Y Brewington;William Parker;Jeffrey L Platt
  • 通讯作者:
    Jeffrey L Platt

Jeffrey L Platt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeffrey L Platt', 18)}}的其他基金

T cell responses and cardiac transplantation in infancy
婴儿期 T 细胞反应和心脏移植
  • 批准号:
    7474547
  • 财政年份:
    2007
  • 资助金额:
    $ 30.95万
  • 项目类别:
Laboratory Core
实验室核心
  • 批准号:
    7474548
  • 财政年份:
    2007
  • 资助金额:
    $ 30.95万
  • 项目类别:
T cell responses and cardiac transplantation in infancy
婴儿期 T 细胞反应和心脏移植
  • 批准号:
    7312642
  • 财政年份:
    2006
  • 资助金额:
    $ 30.95万
  • 项目类别:
Laboratory Core
实验室核心
  • 批准号:
    7312643
  • 财政年份:
    2006
  • 资助金额:
    $ 30.95万
  • 项目类别:
T cell responses and cardiac transplantation in infancy
婴儿期 T 细胞反应和心脏移植
  • 批准号:
    7124860
  • 财政年份:
    2005
  • 资助金额:
    $ 30.95万
  • 项目类别:
Cardiac Transplantation in Infancy
婴儿期心脏移植
  • 批准号:
    7686269
  • 财政年份:
    2005
  • 资助金额:
    $ 30.95万
  • 项目类别:
Laboratory Core
实验室核心
  • 批准号:
    7124872
  • 财政年份:
    2005
  • 资助金额:
    $ 30.95万
  • 项目类别:
Cardiac Transplantation in Infancy
婴儿期心脏移植
  • 批准号:
    7123786
  • 财政年份:
    2005
  • 资助金额:
    $ 30.95万
  • 项目类别:
Cardiac Transplantation in Infancy
婴儿期心脏移植
  • 批准号:
    6955097
  • 财政年份:
    2005
  • 资助金额:
    $ 30.95万
  • 项目类别:
Administrative
行政的
  • 批准号:
    7124867
  • 财政年份:
    2005
  • 资助金额:
    $ 30.95万
  • 项目类别:

相似海外基金

Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10722686
  • 财政年份:
    2023
  • 资助金额:
    $ 30.95万
  • 项目类别:
Lipid peroxidation- and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulation
病原体诱导的血液凝固中脂质过氧化和焦亡诱导的组织因子激活
  • 批准号:
    10571353
  • 财政年份:
    2023
  • 资助金额:
    $ 30.95万
  • 项目类别:
Elucidation of changes in electrical properties during the blood coagulation process and its use for measurement of blood coagulation status during extracorporeal circulation
阐明血液凝固过程中电特性的变化及其在体外循环期间血液凝固状态测量中的应用
  • 批准号:
    23K08266
  • 财政年份:
    2023
  • 资助金额:
    $ 30.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SBIR Phase II: Innovative Platform for Low Volume Blood Coagulation Analysis
SBIR II 期:低容量凝血分析的创新平台
  • 批准号:
    2134020
  • 财政年份:
    2022
  • 资助金额:
    $ 30.95万
  • 项目类别:
    Cooperative Agreement
Construction of a multilayered network to represent blood coagulation process
构建代表血液凝固过程的多层网络
  • 批准号:
    22K12252
  • 财政年份:
    2022
  • 资助金额:
    $ 30.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Protein S Regulates Blood Coagulation by Inhibiting Factor IXa
Protein S 通过抑制 IXa 因子调节凝血
  • 批准号:
    10616732
  • 财政年份:
    2022
  • 资助金额:
    $ 30.95万
  • 项目类别:
Development of thrombus prevention technology for ECMO devices based on the blood coagulation mechanism caused by viral infections
基于病毒感染凝血机制的ECMO装置血栓预防技术开发
  • 批准号:
    21K08817
  • 财政年份:
    2021
  • 资助金额:
    $ 30.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10452687
  • 财政年份:
    2021
  • 资助金额:
    $ 30.95万
  • 项目类别:
SBIR Phase II: CoagCare-A POC Blood Coagulation Diagnostic Platform That Utilizes A Hand-held Meter and Mechanically Sensitive Test Strips for Broad Spectrum Hemostasis Monitoring
SBIR II 期:CoagCare - POC 凝血诊断平台,利用手持式仪表和机械敏感试纸条进行广谱止血监测
  • 批准号:
    2050272
  • 财政年份:
    2021
  • 资助金额:
    $ 30.95万
  • 项目类别:
    Cooperative Agreement
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10283268
  • 财政年份:
    2021
  • 资助金额:
    $ 30.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了